Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.

Tvardi Therapeutics (TVRD) stock jumps 50% after reporting positive Phase 1 data for its next-gen STAT3 inhibitor, TTI-109. Read more.

Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.